Nebenwirkungen · Yescarta
Yescarta 0.4 – 2 × 108 cells dispersion for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-139705 · Präparat HOS-098384
Neurologic adverse reactions In ZUMA-1 and ZUMA-7, neurologic adverse reactions occurred in 63% of patients. Twenty-five percent (25%) of patients experienced Grade 3 or higher (severe or life-threatening) adverse reactions. Neurologic toxicities occurred within the first 7 days of infusion for 75% of patients. The median time to onset was 6 days (range: 1 to 133 days). The median duration was 10 days, with resolution occurring within 3 weeks for 66% of patients following infusion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-08T14:29:00Z · SHA-256 7364b8713752a41eb6e8333150b68c1c6ab4a679e9b42caeedeacec6f055396e · Passage e7e7c20162f6c8c368c5a9bffdae90470afc105ee613422acead3fc39587573c · Zeichen 18903–19389 im Abschnitt